Evidence map›Paper›PMID 40208273›Full record

ArticleCellular and molecular life sciences : CMLS2025

Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer.

Dannel Yeo, Doruk Seyfi, Althea Bastian, Heidi Strauss, Anna Leach, Vera Klemm, Anthony Pirrello, Kevin Spring, Payal Saxena, Sara Wahlroos and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Novel Liquid Biopsy in Gastrointestinal Cancers.Journal of gastroenterology and hepatology · 2026
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dannel YeoLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, Australia.ORCID http://orcid.org/0000-0002-6546-1209
Doruk SeyfiDepartment of Hepatobiliary and Upper Gastrointestinal Surgery, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, Australia.
Althea BastianLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, Australia.
Heidi StraussLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, Australia.
Anna LeachLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, Australia.
Vera KlemmLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, Australia.
Anthony PirrelloLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, Australia.
Kevin SpringMedical Oncology Group, Liverpool Clinical School, School of Medicine, Western Sydney University and Ingham Institute for Applied Medical Research, Liverpool, Australia.
Payal SaxenaDivision of Gastroenterology, Department of Medicine, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, Australia.
Sara WahlroosMedical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia.
Sarah SutherlandFaculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Peter GrimisonFaculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Jin-Soo ParkFaculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Charbel SandroussiFaculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
John Ej RaskoLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, Australia. jejrasko@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic cancer is an aggressive disease with poor prognosis. The only potentially curative treatment option is surgical resection, however recurrence is common. Biomarkers to detect minimal residual disease, assist with risk stratification, relapse and real time monitoring, are required. Circulating tumor cells (CTCs) are a promising liquid biopsy biomarker for solid tumors. However, their role in monitoring minimal residual disease in pancreatic cancer remains to be determined. Our study aimed to investigate whether detection and enumeration of CTCs could predict recurrence and provide monitoring of disease status.

methodParticipants planned for Whipple procedure or partial pancreatectomy were enrolled in this prospective pilot study. Intraoperatively, 7.5 mL of portal and peripheral venous blood were collected, and peripheral venous blood was also collected post-surgery. CTC identification and enumeration were performed using the AccuCyte-CyteFinder platform and CellSieve microfiltration.

resultsOf 29 participants, 20 were confirmed to have epithelial cancer by histopathology, where 15 had pancreatic ductal adenocarcinoma. In those with epithelial cancer, CTCs were detected intraoperatively in 75% of portal venous blood samples, in contrast to 40% detected in peripheral venous blood (median: 6 and 0 per 7.5mL respectively). Only portal venous CTC detection was predictive of pancreatic ductal adenocarcinoma relapse. The positive (> 5) portal venous CTC group had a 6.67 times higher risk of recurring (odds ratio = 20.43, sensitivity = 1.00, specificity = 0.625). Detection of peripheral venous CTCs post-surgery was also correlated with relapse in a small subset of patients.

conclusionsIf validated, CTCs may provide a prognostic and monitoring biomarker in patients with pancreatic cancer undergoing surgery.

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalNeoplasm Recurrence, LocalNeoplastic Cells, CirculatingPancreatic NeoplasmsPortal VeinAdultAgedFemaleHumansLiquid BiopsyMaleMiddle AgedPilot ProjectsPrognosisProspective StudiesBiomarkers, TumorBiomarkersLiquid biopsyMinimal residual diseasePortal venousPrecision medicineRisk assessment

Identifiers

PMID40208273
PMCPMC11985722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.